TABLE 7.
Predictive factors for PFS of crizotinib in crizotinib‐resistant patients (n = 52)
| Variable | Univariable analysis, p‐value | Multivariable analysis | |
|---|---|---|---|
| Hazard ratio (95% CI) | p‐value | ||
| Age | HR = 2.063 | p = 0.211 | |
| ≥65 vs. <65 | 0.05 | (95% CI: 0.663–6.417) | |
| Gender | HR = 0.454 | p = 0.010 | |
| Female vs. male | 0.003 | (95% CI: 0.248–0.830) | |
| ECOG | HR = 2.811 | p = 0.006 | |
| ≥2 vs. 0–1 | 0.003 | (95% CI: 1.355–5.835) | |
| Smoking history | |||
| Smoker vs. never smoker | 0.392 | ‐ | |
| Stage | |||
| III or recurrence without distant metastases | |||
| vs. | 0.475 | ‐ | |
| IV or recurrence with distant metastases | |||
| Distant organs involved | HR = 1.883 | p = 0.115 | |
| ≥3 vs. ≤2 | 0.077 | (95% CI: 0.857–4.137) | |
| CNS metastases | |||
| Yes vs. no | 0.671 | ‐ | |